Publications

Filter Publications By:

Filanesib / Multiple Myeloma

12/07/2013

American Society of Hematology Annual Meeting

A Phase 1 Study of ARRY-520 (Filanesib) with Bortezomib in Relapsed or Refractory Multiple Myeloma

A. Chari, M.D., et al.

Filanesib / Multiple Myeloma

12/07/2013

American Society of Hematology Annual Meeting

Phase I Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib (ARRY-520) + Carfilzomib (Car) in Patients with Relapsed and/or Refractory Multiple Myeloma

J.J. Shah, MD, et al.

ARRY-382 / CSF1R

11/01/2013

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

A Phase 1 Study of ARRY-382, an Oral Inhibitor of Colony-stimulating Factor-1 Receptor (CSF1R), in Patients with Advanced or Metastatic Cancers

J. Bendell, M.D., et al.

Filanesib / Multiple Myeloma

10/16/2013

International Society for the Study of Xenobiotics International Meeting

The Role of Alpha 1-Acid Glycoprotein (AAG) as a Selection Marker for ARRY-520 Exposure

K. D. Brown, et al.

ARRY-380 / Breast Cancer

10/07/2013

American Association for Cancer Research Special Conference on Advances in Breast Cancer Research

ONT-380 (ARRY-380) - an Oral HER2 Inhibitor - Final Phase 1 Results and Conclusions

V. F. Borges, et al.

Binimetinib / Cancer

09/30/2013

European Society for Medical Oncology Congress

Results of a phase 1 study of MEK162, an oral MEK inhibitor, in Japanese patients with advanced solid tumors

T. Shimokata, et al.

Encorafenib / Cancer

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Binimetinib / Cancer

07/13/2013

International Melanoma Conference

Initial Results from an Open-label, Dose-escalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600-mutant Advanced Melanoma

R. Dummer, et al.

Encorafenib / Cancer

07/12/2013

International Melanoma Conference

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination with the Oral MEK1/2 Inhibitor MEK162 in BRAF V600-Dependent Advanced Solid Tumors

R. Kefford, et al.

Encorafenib / Cancer

07/12/2013

World Congress of Melanoma

Preliminary Results From a Phase Ib/II, Open-Label, Dose-Escalation Study of the Oral Selective BRAF Inhibitor LGX818 in Combination With the Oral MEK1/2 Inhibitor MEK162 in BRAF V600–Dependent Advanced Solid Tumors

R. Kefford, et al.